- Home
- MIRM vs GTX Comparison
MIRM vs GTX Comparison
Compare MIRM & GTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | GTX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.2B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIRM | GTX |
|---|---|---|
| Price | $91.20 | $25.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $119.85 | $20.40 |
| AVG Volume (30 Days) | 464.4K | ★ 2.5M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | ★ 74.59 | 20.63 |
| EPS | N/A | ★ 0.49 |
| Revenue | $19,138,000.00 | ★ $3,584,000,000.00 |
| Revenue This Year | $26.22 | $4.16 |
| Revenue Next Year | $22.04 | $3.27 |
| P/E Ratio | ★ N/A | $53.88 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $63.23 | $12.26 |
| 52 Week High | $130.00 | $36.25 |
Technical Indicators
Market Signals| Indicator | MIRM | GTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 42.65 |
| Support Level | $88.08 | $25.55 |
| Resistance Level | $98.03 | $28.38 |
| Average True Range (ATR) | 3.90 | 0.76 |
| MACD | -0.37 | 0.07 |
| Stochastic Oscillator | 10.13 | 35.93 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.